Vilon
- Category
- Bioregulators
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
Vilon is a synthetic dipeptide (Lys-Glu) marketed to support immune recovery and thymic function in aging. Human evidence for these effects is limited and preliminary, and claims about tumor inhibition and cellular aging pathways rely on speculative animal and mechanistic studies. Safety data is limited, and it may interact with high-dose cyclophosphamide in cancer patients. It is not an FDA-approved drug and is available only as unregulated products sold online.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Vilon is a synthetic 2-amino-acid peptide (Lys-Glu) from the Khavinson bioregulator family — believed to be the shortest peptide ever documented to produce significant biological effects. Originally identified as one of the key active components in Thymalin (a calf thymus extract), it was developed at the St. Petersburg Institute of Bioregulation and Gerontology to support immune function and counter the age-related decline of the thymus gland.
How it works in the body
A dipeptide bioregulator (Lys-Glu) that targets thymic epithelial cells and thymocytes. It interacts with chromatin in these cells to regulate the expression of genes involved in T lymphocyte maturation, thymic peptide secretion, and the maintenance of immune competence during aging.
Research overview
Vilon is proposed to work by binding to specific DNA sequences in the promoters of key longevity and repair genes — including SIRT1 (a central longevity gene) and PARP1/PARP2 (DNA repair genes) — effectively reactivating genes that become silenced with age. In elderly immune cells, it selectively 'unrolls' age-condensed DNA without disrupting structural regions, restoring more youthful gene expression patterns. In mice, subcutaneous Vilon inhibited spontaneous tumor growth and extended lifespan. It also protected thymus and spleen tissue in radiation-induced aging models and enhanced stress resistance in rats. About 25-35 peer-reviewed papers exist, including a 2022 collaboration with Italian researchers. Limited human data suggests improved survival in elderly cancer patients receiving it alongside standard treatment. However, most studies originate from Khavinson-affiliated groups, no Western randomized controlled trials exist, and the human evidence is preliminary.
Who researches Vilon?
Commonly researched by
People researching immune system support
Studied for immune modulation, antiviral, or antimicrobial properties.
People researching inflammation management
Studied for anti-inflammatory effects across various conditions.
People researching GI and digestive health
Studied for gastrointestinal protection, gut lining repair, or digestive support.
People researching longevity and anti-aging interventions
Studied for effects on aging pathways, cellular health, or lifespan extension.
People researching experimental oncology peptides
Studied for effects on cancer cell targeting or tumor biology in preclinical research.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(5)
Rated by level of concern
Limited safety data and lack of independent validation
HighAbsence of Vilon/Lys-Glu records on ClinicalTrials.gov and FDA databases; single-network publication pattern evident across the PubMed record (e.g. PMID 24003726 clinical review)
Potential immunostimulatory effects in autoimmune conditions
TheoreticalMechanistic inference from PMID 12447482 (in vitro IL-2 gene expression in splenocytes) and PMID 23486604 (thymus cell immunomodulation); no autoimmune outcome studies located
Negative interaction with high-dose cyclophosphamide noted in research
ModeratePMID 14743610 (combined effect of vilon and cyclophosphane on tumor transplants and lymphoid tissue explants)
Unregulated product quality
HighFDA regulatory status: not an approved drug and not on the FDA 503A/503B bulk-compounding lists
Mild transient side effects
LowPMID 11140587 (long-term administration caused no unfavourable effects on animal development); no systematic human AE reporting located
Interaction summary(7)
Rated by direction with this peptide
Cyclophosphamide and other cytotoxic alkylating chemotherapy
CautionModerateSimultaneous Vilon plus high-dose cyclophosphamide reduced tumor-bearing mouse survival versus either agent alone, and Vilon abolished cyclophosphamide's antiproliferative effect in lymphoid organ culture - the investigators concluded the two must not be given synchronously (PMID 14743610).
PMID 14743610
Ionizing radiation / radiotherapy (normal-tissue exposure)
ProtectiveLowIn rodent models Vilon partially preserved thymic and splenic architecture after irradiation and after repeated low-dose radiation, and inhibited irradiation-induced lymphocyte apoptosis (PMID 11276315, 'peptide bioregulators inhibit apoptosis'). The same tissue-protective and antiapoptotic action is untested against tumor tissue, so it should not be assumed safe alongside curative-intent radiotherapy.
PMID 12096431; PMID 11427924; PMID 16075682; PMID 11276315 (peptide bioregulators inhibit apoptosis)
Immunosuppressants (calcineurin inhibitors, corticosteroids, post-transplant regimens)
CautionTheoreticalVilon's documented restoration of thymocyte differentiation and IL-2 expression runs directly counter to the goal of pharmacologic immunosuppression, so pharmacodynamic antagonism is plausible in transplant or autoimmune patients although it has never been tested.
Mechanistic inference from PMID 23486604 and PMID 12447482; no interaction study exists
Immune checkpoint inhibitors and other cancer immunotherapy
CautionTheoreticalVilon's tumor effects become context-dependent in combination settings (it aided survival alone but reduced it with cyclophosphamide, PMID 14743610) and its antiapoptotic effects on lymphoid tissue make the net direction alongside checkpoint blockade genuinely unpredictable. No clinical data exist.
PMID 14743610 (context-dependent combination effect); PMID 11276315; no clinical data
Anticoagulants and antiplatelet agents
CautionLowA human study in type 1 diabetes patients (PMID 17152731) found Vilon acts on the coagulation system - reducing hypercoagulability and DIC and improving impaired fibrinolysis (i.e. an anticoagulant/profibrinolytic-leaning effect). An additive bleeding risk with warfarin, DOACs, or antiplatelets is therefore plausible, though no interaction has been formally assessed.
PMID 17152731
Epithalon (AEDG / Ala-Glu-Asp-Gly) and other Khavinson short peptides
SynergisticLowVilon and Epithalon are repeatedly co-administered in the source literature with complementary, largely non-overlapping effects on cardiac gene expression, nucleolar organizer region activity, and intestinal enzyme activity, consistent with additive rather than conflicting action.
PMID 12360356; PMID 15455093; PMID 12660839
Antidiabetic therapy (insulin, oral agents)
NeutralLowVilon has been given to diabetic patients of varying ages in small Russian studies with reported effects on immune and hemostatic indices but no described interference with glycemic control or insulin requirements.
PMID 18306698; PMID 17152731
Known risks(5)
Limited safety data and lack of independent validation
ModerateAll safety data originates from Khavinson-affiliated research groups with small sample sizes. No independent safety monitoring, pharmacovigilance, or large-scale safety trials have been conducted. No FDA review of safety has occurred. The absence of adverse events in published studies may reflect small sample sizes rather than true absence of risk. No dedicated English-language safety studies exist outside the Khavinson research framework.
Potential immunostimulatory effects in autoimmune conditions
ModerateVilon stimulates T-cell differentiation, thymocyte proliferation, and immune cell activation. In individuals with autoimmune diseases (rheumatoid arthritis, lupus, multiple sclerosis, type 1 diabetes), immune stimulation could theoretically exacerbate autoimmune responses. No studies have specifically evaluated Vilon in autoimmune populations. Use should be approached with caution and medical supervision in these conditions.
Negative interaction with high-dose cyclophosphamide noted in research
ModerateOne rodent study found that Vilon given concurrently with very high-dose cyclophosphamide led to a decline in survival of mice with transplanted Lewis lung carcinoma (PMID 14743610). Although the chemotherapy exposure was supraphysiologic, it suggests that Vilon's immunomodulatory effects may interact unpredictably with certain cytotoxic agents. Active chemotherapy patients should exercise particular caution.
Unregulated product quality
ModerateUnregulated Vilon products sold online are not manufactured under pharmaceutical GMP standards and are not subject to FDA quality oversight. Purity, identity, and sterility may vary among them. Contamination, endotoxin levels, or incorrect peptide sequences are potential concerns.
Mild transient side effects
LowReported side effects are rare and minor: injection site irritation and transient fatigue. No notable serious adverse events have been identified in published literature. Human safety remains poorly characterized. Vilon increased mammary tumor development in one genetically susceptible mouse model; the relevance to humans is unknown.
Drug interactions(5)
Immunosuppressants (cyclosporine, tacrolimus, mycophenolate, azathioprine)
Vilon stimulates T-cell differentiation, thymocyte proliferation, and immune cell activation. These effects could theoretically counteract the mechanism of immunosuppressant drugs, reducing their efficacy. Patients on immunosuppression for organ transplant, autoimmune disease, or other conditions should not use Vilon without medical supervision. No interaction studies have been conducted.
Cytotoxic chemotherapy agents (cyclophosphamide and related alkylating agents)
One rodent study (PMID 14743610) found that Vilon given with very high-dose cyclophosphamide reduced survival of mice with transplanted Lewis lung carcinoma. Although the chemotherapy exposure was supraphysiologic, this suggests an unpredictable interaction between Vilon's immunomodulatory effects and cytotoxic chemotherapy. Active chemotherapy patients should exercise caution.
Corticosteroids (prednisone, dexamethasone, hydrocortisone)
Corticosteroids are known to cause thymic involution and lymphocyte apoptosis — effects that directly oppose Vilon's thymocyte-stimulating and anti-apoptotic mechanisms. Concurrent use could result in conflicting pharmacological signals. No interaction data exists, but the opposing mechanisms suggest potential for diminished efficacy of either agent.
Biological immunomodulators (TNF-alpha inhibitors, IL-6 inhibitors, checkpoint inhibitors)
Vilon has been shown to modulate TNF and IL-6 cytokine expression in macrophage models. Co-administration with biological agents targeting the same cytokine pathways (e.g., infliximab, adalimumab, tocilizumab) could produce additive or unpredictable effects on immune regulation. No interaction studies have been conducted.
Other Khavinson peptide bioregulators (Thymalin, Epithalon, Thymogen, Pinealon)
Vilon and Thymogen (EW dipeptide) are both active fragments of Thymalin, so using them together supplies key components of the parent compound. The study in elderly cancer patients used Vilon within a complex treatment scheme (PMID 16075684). No formal interaction studies have been conducted.
Research & benefits
Evidence base
- Evidence Level
- Limited Evidence
- Total Studies
- 28
- Human Studies
- 2
The clinical evidence for Vilon is limited in human studies but extensive in preclinical models. The strongest human evidence comes from the study of elderly cancer patients receiving Vilon as an immunomodulator in complex radical treatment, with preliminary results suggesting improved 2-year survival, prevention of post-operative complications, and improved quality of life (PMID 16075684). The cited long-term human study administered Thymalin and Epithalamin; it does not establish long-term efficacy or safety of isolated Vilon. Preclinical findings are mixed, including increased mammary tumor development in one HER-2/neu mouse model. Other preclinical studies report that Vilon extends lifespan by 20-40% in mice, inhibits spontaneous and carcinogen-induced tumor development, protects thymus and spleen from radiation-induced aging, reactivates chromatin in elderly lymphocytes, upregulates SIRT1 by 6-8x in human stem cells, reduces pro-inflammatory cytokines (TNF, IL-6) in monocyte/macrophage models, improves digestive enzyme activity in aged animals, and reduces TGF-beta and microvessel permeability in chronic renal failure. Major limitations include Khavinson-group origin for nearly all studies, small sample sizes, lack of randomized controlled trials, and absence of formal clinical development outside Russia.
Researched for(8)
Rated by confidence in the evidence
Immune system restoration and thymic function support
MediumSupported by human thymus cell culture studies and small open-label clinical reports in elderly patients.
PMID 23486604 (immunomodulating effects in human/animal thymus cell culture); PMID 22238759 (peptidergic regulation of thymocyte differentiation, proliferation, apoptosis in thymic aging); PMID 15455093 (NOR argyrophilic proteins in human thymocytes/epitheliocytes); PMID 18306698 (immunity status in diabetic patients of different ages); PMID 24003726 (clinical studies review)
Inhibition of spontaneous tumor growth and lifespan extension
LowExtended lifespan and reduced spontaneous tumors in mice across several studies, no human longevity data.
PMID 10944717 (dipeptide vilon inhibits spontaneous tumors, increases life span of mice); PMID 11140587 (biological age and lifespan in mice); PMID 11163623 (biomarkers of aging, survival, spontaneous tumour incidence in female CBA mice)
Epigenetic chromatin reactivation in aging lymphocytes
LowDemonstrated in cultured lymphocytes from elderly donors across multiple studies, no in vivo data yet.
PMID 15105581 (Vilon-induced reactivation of chromatin in lymphocytes from old people); PMID 16705247 (anti-aging peptide bioregulators induce reactivation of chromatin); PMID 15085253 (short peptides on lymphocyte chromatin in senile subjects); PMID 37042594 (epigenetic modification of 'old' chromatin)
SIRT1 upregulation and PARP1/PARP2 modulation during cellular aging
SpeculativeSingle human stem cell study showing SIRT1 increase and PARP1/PARP2 decrease, in vitro only.
PMID 37782636 (KE peptide regulates SIRT1, PARP1, PARP2 in human MSC aging); PMID 33231794 (KE vs AED peptides in replicatively aging human skin fibroblasts)
Anti-inflammatory and immunomodulatory effects on monocytes/macrophages
SpeculativeEffects shown only in immortalized monocyte cell lines and aging mouse macrophages, no human data.
PMID 35408963 (peptides regulating proliferative activity and inflammatory pathways in THP-1); PMID 17426849 (lymphocyte-activating factors by mouse macrophages during aging and under short peptides)
Protection of thymus and spleen in radiation-induced premature aging
LowPreserved thymus and spleen structure in rodent radiation-aging models, no human radioprotection data.
PMID 12096431 (vilon on thymus and spleen in a radiation model of premature aging); PMID 11427924 (immunohistochemical/morphometric analysis of radiosensitive organs); PMID 16075682 (repeated low-dose radioactive and mercuric impact)
Inhibition of carcinogen-induced neoplasia
LowA rat bladder-cancer model reported tumor inhibition, but Vilon increased mammary tumor development in a HER-2/neu mouse model. These animal studies do not establish human preventive benefit.
PMID 11586406 (induced rat urinary bladder tumors); PMID 11785104 (induction and growth of induced bladder neoplasms); PMID 16308980 (vilon on 1,2-dimethylhydrazine-induced neoplasia); PMID 12101568 (Epitalon and Vilon on mammary carcinogenesis in erbB-2/NEU mice)
Improved digestive enzyme activity and nutrient absorption in aging
LowAltered digestive enzyme activity and nutrient absorption in aged rats across three studies, no human data.
PMID 11586413 (dipeptide vilon on digestive enzyme activity in rats of various ages); PMID 12660839 (vilon and epithalon on enzymes in epithelial/subepithelial layers of small intestine of old rats); PMID 12420071 (glucose and glycine absorption in small intestine of aged rats)
Benefits(8)
Immune system restoration and thymic function support
Khavinson et al. (Bulletin of Experimental Biology and Medicine, PMID 23486604) — Vilon and its analogues increased expression of lymphocyte differentiation marker CD5 in human and animal thymic cell cultures, stimulated differentiation of T-cell precursors into CD4+ T-helpers and CD8+ cytotoxic T lymphocytes, and enhanced B-cell maturation. The effect positions Vilon as an immunomodulator capable of restoring T-cell production capacity in aging or immunocompromised thymus tissue. Anisimov et al. (Bulletin of Experimental Biology and Medicine, PMID 11427924) — Immunohistochemical and morphometric analysis demonstrated Vilon stimulated proliferative activity of thymocytes and enhanced proliferative potential of stem cells in the intestine, promoting postradiation recovery of critical immune organs.
Inhibition of spontaneous tumor growth and lifespan extension
Khavinson and Anisimov 2000 (Doklady Biological Sciences, PMID 10944717) — Subcutaneous administration of Vilon (Lys-Glu) to female CBA mice starting from the 6th month of life increased physical activity and endurance, decreased body temperature, prolonged lifespan, and prevented development of spontaneous neoplasms. Long-term treatment with peptide preparations increased mean life span by 20-40% and suppressed tumorigenesis. Anisimov et al. 2000 (Biogerontology, PMID 11140587) — Effect of Vilon on biological age and lifespan in mice: chronic administration caused no unfavorable effects on animal development.
Epigenetic chromatin reactivation in aging lymphocytes
Khavinson et al. 2004 (Bulletin of Experimental Biology and Medicine, PMID 15105581) — Bioregulator Vilon induced reactivation of chromatin in cultured lymphocytes from elderly individuals (ages 75-88). Vilon induced unrolling (deheterochromatinization) of total heterochromatin and released genes repressed by age-specific condensation of euchromatic regions. Khavinson et al. 2006 (Rejuvenation Research, PMID 16705247) — Peptide bioregulators Epitalon, Livagen, and Vilon caused activation of chromatin in lymphocytes of old individuals, activating ribosome genes and decondensing densely packed chromatin fibrils.
SIRT1 upregulation and PARP1/PARP2 modulation during cellular aging
Khavinson et al. 2023 (Advances in Gerontology, PMID 37782636) — The KE peptide increased gene expression and synthesis of SIRT1 protein in 'young' human mesenchymal stem cells by 6 and 8.2 times, respectively. During MSC aging, KE peptide reduced PARP1 gene expression and protein synthesis by 2.1 and 5.3 times, and reduced PARP2 gene expression and protein synthesis by 2.1 and 4.7 times. The KE peptide interacts with GCGG and GGGC DNA sequences found in the promoters of human SIRT1, PARP1, and PARP2 genes, providing a molecular mechanism for its geroprotective effects.
Anti-inflammatory and immunomodulatory effects on monocytes/macrophages
Khavinson et al. 2022 (International Journal of Molecular Sciences, PMID 35408963) — Vilon and other Khavinson peptides were evaluated in the THP-1 monocyte/macrophage cell line. All peptides including Vilon inhibited expression of TNF and pro-inflammatory IL-6 cytokine stimulated by LPS on terminally differentiated THP-1 cells. Results suggest Khavinson peptides cooperate as natural inducers of TNF tolerance in monocytes and act as anti-inflammatory molecules during inflammatory and microbial-mediated activity. Vilon showed modulatory capacity on ERK1/2 phosphorylation.
Protection of thymus and spleen in radiation-induced premature aging
Kniaz'kin and Poliakova 2002 (Advances in Gerontology, PMID 12096431) — Low-dose ionizing radiation induced accelerated aging of the thymus and spleen in rats; treatment with synthetic dipeptide Vilon partially inhibited this process. Vilon is considered a candidate for geriatric research and practice. Khavinson et al. (Bulletin of Experimental Biology and Medicine, PMID 11276315) — Vilon inhibits physiologically programmed cell death and radiation-induced apoptotic death of spleen lymphocytes, with the antiapoptotic effect being particularly pronounced.
Inhibition of carcinogen-induced neoplasia
Anisimov et al. 2005 (Voprosy Onkologii, PMID 16308980) — After treatment with Vilon at 10 mcg/kg, 1,2-dimethylhydrazine-induced tumors developed in only 14.3% of animals surviving to first tumor detection (46 weeks), compared with 60% in controls. Anisimov et al. 2001 (Voprosy Onkologii, PMID 11785104) — Treatment with Vilon reduced bladder tumor incidence to 56% of experimental animals compared with 75.5% in controls following carcinogen challenge.
Improved digestive enzyme activity and nutrient absorption in aging
Khavinson et al. 2001 (Bulletin of Experimental Biology and Medicine, PMID 11586413) — Peroral administration of Vilon to Wistar rats aged 3 and 11 months changed activity of digestive enzymes (invertase, maltase, alkaline phosphatase, amino- and dipeptidases) in various portions of the gastrointestinal tract. Increases were most pronounced in 11-month-old animals, diminishing age-related differences. Khavinson et al. 2002 (Bulletin of Experimental Biology and Medicine, PMID 12660839) — Oral Vilon for 1 month significantly increased membrane enzyme activity (maltase, alkaline phosphatase) in the epithelial layer of the small intestine in aged rats.
Key studies(5)
A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice
Experimental animal study (mouse, longitudinal)Female CBA mice, multiple treatment groupsLifetime (treatment from 6th month of life)Khavinson VKh, Anisimov VN
Doklady Biological Sciences
2000
Subcutaneous administration of Vilon (Lys-Glu) to female CBA mice starting from the 6th month of life increased physical activity and endurance, decreased body temperature, prolonged lifespan, and prevented development of spontaneous neoplasms. Long-term treatment with peptide preparations increased mean life span by 20-40% and suppressed the development of spontaneous and induced tumorigenesis in rodents. Chronic Vilon administration caused no unfavorable effects on animal development, demonstrating safety of long-term use for geroprotection.
KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal stem cells aging
Experimental research (in vitro, human mesenchymal stem cells)Human MSCs at young and senescent passagesCell culture experiment with aging modelKhavinson VK, Linkova NS, Ashapkin VV, Shilovsky GA, Borushko NV, Petukhov MG, Vanuyshin BF
Advances in Gerontology
2023
The KE peptide increased SIRT1 gene expression and protein synthesis in 'young' MSCs by 6 and 8.2 times respectively. During MSC aging, KE peptide reduced PARP1 gene expression and protein synthesis by 2.1 and 5.3 times, and PARP2 by 2.1 and 4.7 times. The peptide interacts with GCGG and GGGC DNA sequences in the promoters of human SIRT1, PARP1, PARP2 genes. Provides a molecular mechanism linking the KE dipeptide to key longevity-associated pathways (sirtuin activation, DNA repair modulation).
Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
Experimental research (in vitro, THP-1 monocyte/macrophage cell line)THP-1 cell line, PMA-differentiated macrophages, LPS-stimulatedCell culture experimentAvolio F, Martinotti S, Khavinson VKh, et al.
International Journal of Molecular Sciences
2022
Vilon and other Khavinson peptides inhibited expression of TNF and pro-inflammatory IL-6 stimulated by LPS on terminally differentiated THP-1 cells. The peptides cooperate as natural inducers of TNF tolerance in monocytes and act as anti-inflammatory molecules during inflammatory and microbial-mediated activity. Vilon showed modulatory capacity on ERK1/2 phosphorylation. This study represents international collaboration with Italian researchers at the University of Chieti.
Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people
Experimental research (in vitro, human lymphocytes from elderly donors)Lymphocytes from donors aged 75-88 yearsCell culture experimentLezhava T, Khavinson V, Monaselidze J, Jokhadze T, Dvalishvili N, Bablishvili N, Barbakadze Sh
Biogerontology
2004
Vilon induced reactivation of chromatin in cultured lymphocytes from elderly individuals. It caused unrolling (deheterochromatinization) of total heterochromatin and released genes repressed by age-specific condensation of euchromatic regions, while not affecting pericentromeric structural heterochromatin. This selective chromatin remodeling provides evidence for the mechanism by which Vilon restores youthful gene expression patterns in aging immune cells.
The effect of vilon on the thymus and spleen in a radiation model of premature aging
Experimental animal study (rat, radiation model)Wistar rats subjected to low-dose ionizing radiationRadiation-induced premature aging protocol with Vilon treatmentKniaz'kin IV, Poliakova VO
Advances in Gerontology (Uspekhi Gerontologii)
2002
Low-dose ionizing radiation induced accelerated aging of the thymus and spleen in rats. Treatment with synthetic dipeptide Vilon (Lys-Glu) partially inhibited this process, protecting immune organ morphology and function. Vilon stimulated proliferative activity of thymocytes and enhanced proliferative potential of stem cells in the intestine, promoting postradiation recovery of critical organs. Results position Vilon as a candidate for geriatric research and practice.
Regulation & availability
Why researchers look at it
Animal studies show 20-40% lifespan extension and 70-80% reduction in carcinogen-induced tumors, with in vitro work demonstrating 6-8 fold SIRT1 upregulation and selective reactivation of age-silenced chromatin in elderly immune cells — all from just two amino acids. Nearly all studies originate from Khavinson-affiliated groups with no independent Western replication. If confirmed in rigorous human trials, a dipeptide that restores youthful gene expression would be a remarkable finding for aging biology.
- Estimated cost
- $30-80/mo oral capsules
- FDA status
- Vilon is not FDA-approved and is not eligible for compounding in the US. No public confirmation of an IND, NDA or BLA submission for Vilon was identified; FDA generally does not disclose IND existence unless it has previously been publicly disclosed or acknowledged.
- WADA status
- Not named in the 2026 List. S0 prohibits otherwise-unlisted pharmacological substances lacking governmental approval for human therapeutic use. Lack of a named entry does not establish permission; obtain an anti-doping determination.
- Prescribability
- Vilon is not FDA-approved and is not eligible for compounding in the US. No established pathway for routine compounding from bulk Vilon was identified under sections 503A or 503B; a prescription alone does not establish ingredient eligibility. In Russia and some CIS countries, Vilon has been used within the framework of the St. Petersburg Institute of Bioregulation and Gerontology's clinical protocols, but it is not registered as a standalone pharmaceutical by the Russian Ministry of Health.
- Availability
- Vilon is not part of mainstream Western medicine. Vilon has been used within Khavinson's clinical framework at the St. Petersburg Institute of Bioregulation and Gerontology for immunomodulatory and geroprotective protocols. Unlike Thymalin (the parent thymus extract, which is an approved pharmaceutical in Russia), Vilon as a standalone dipeptide does not appear to have its own pharmaceutical registration. Vilon is not available through US or EU pharmacies, not listed in any Western pharmacopeia, and cannot be obtained through standard prescription channels.
International status
EU
Not approved
US
Not approved
Russia
Used clinically (Khavinson bioregulator protocol)
Worldwide
Limited to Russian clinical use
Regulatory timeline(15)
- 1971Vladimir Khavinson begins research on peptide bioregulators as part of a Soviet military research program at the Military Medical Academy in Leningrad (St. Petersburg).
- 1981-1982Thymalin — a polypeptide complex from calf thymus — is developed by Morozov and Khavinson and becomes the first Khavinson peptide drug. Thymalin later proves to contain the KE (Vilon) and EW (Thymogen) dipeptides as key active components.
- 1980sThe Lys-Glu (KE) dipeptide is identified within Thymalin as one of its active immunomodulatory fragments. Subsequently synthesized as a standalone compound and named 'Vilon.'
- 1992St. Petersburg Institute of Bioregulation and Gerontology (SPIBG) is established as Khavinson's primary research center for peptide bioregulator development.
- 1998Khavinson and Morozov publish review of natural and synthetic thymic peptides as therapeutics for immune dysfunction, positioning Vilon in the broader context of thymic peptide therapy (PMID 9637345).
- 2000Khavinson and Anisimov publish a study reporting that Vilon inhibits spontaneous tumors and extends lifespan by 20-40% in CBA mice (PMID 10944717, Doklady Biological Sciences). A companion study reports no unfavorable effects of chronic administration on development and a reduction in biological age (PMID 11140587).
- 2001Studies published on Vilon's antiapoptotic effects (PMID 11276315), stimulation of postradiation recovery (PMID 11427924), and effects on digestive enzymes in aging (PMID 11586413).
- 2002Multiple publications: Vilon in radiation-induced premature aging model (PMID 12096431), DNA microarray gene expression study (36 clones changed, PMID 12360356), emotional stress resistance in rats (PMID 12587272), nutrient absorption improvement (PMIDs 12420071, 12660839). Khavinson publishes comprehensive review 'Peptides and Ageing' (PMID 12374906).
- 2004Khavinson et al. demonstrate Vilon-induced chromatin reactivation (deheterochromatinization) in lymphocytes from elderly donors aged 75-88 (PMID 15105581).
- 2005Clinical study published on Vilon as immunomodulator in complex treatment of elderly cancer patients, showing improved 2-year survival (PMID 16075684). Carcinogen-induced neoplasia inhibition study published (PMID 16308980).
- 2006Khavinson et al. expand chromatin reactivation findings: Vilon, Epitalon, and Livagen all induce deheterochromatinization in aging lymphocytes (PMID 16705247, Rejuvenation Research).
- 2020Khavinson et al. publish review in Molecules on peptides including KE as prospects for COVID-19 treatment, noting ability to reduce pro-inflammatory cytokine synthesis (IL-1beta, IL-6, TNF-alpha) relevant to cytokine storm (PMC7583759).
- 2022International collaborative study (Russian-Italian) published in International Journal of Molecular Sciences demonstrating Vilon's anti-inflammatory effects on THP-1 monocyte/macrophage cells (PMID 35408963).
- 2023Khavinson et al. publish key mechanistic study: KE peptide regulates SIRT1 (6-8x upregulation), PARP1, and PARP2 gene expression and protein synthesis in human mesenchymal stem cells during aging (PMID 37782636).
- 2026-03No FDA approval for Vilon was identified. No publicly confirmed IND filing was found; FDA generally keeps IND existence confidential. Not included in any ongoing ClinicalTrials.gov registrations.
Sources & FAQs
Research sources(25)
- Khavinson and Anisimov 2000 — Vilon inhibits spontaneous tumors and extends lifespan in mice
- Anisimov et al. 2000 — Effect of Vilon on biological age and lifespan in mice
- Kniaz'kin and Poliakova 2002 — Effect of Vilon on thymus and spleen in radiation aging model
- Anisimov et al. 2002 — Gene expression effects of Vilon and Epithalon (DNA microarray)
- Khavinson et al. 2004 — Vilon-induced chromatin reactivation in elderly lymphocytes
- Khavinson et al. 2006 — Anti-aging peptide bioregulators induce chromatin reactivation
- Khavinson et al. 2005 — Application of Vilon in complex treatment of elderly cancer patients
- Anisimov et al. 2005 — Vilon effect on DMH-induced neoplasia
- Anisimov et al. 2001 — Vilon and Epithalon on induced bladder neoplasms
- Khavinson et al. — Combined effect of Vilon and cyclophosphane on tumor transplants
- Khavinson et al. 2001 — Effect of Vilon on digestive enzyme activity in aged rats
- Khavinson et al. 2002 — Vilon effect on enzymes in small intestine of aged rats
- Khavinson et al. 2002 — Vilon effect on glucose/glycine absorption in aged rats
- Khavinson et al. 2005 — Vilon effect on TGF-beta and microvessel permeability (renal failure)
- Khavinson et al. 2002 — Effect of Vilon on emotional stress resistance in rats
- Khavinson et al. 2013 — Immunomodulating effects of Vilon in human/animal thymus cells
- Khavinson et al. 2001 — Peptide bioregulators inhibit apoptosis
- Khavinson et al. 2001 — Morphometric analysis of Vilon/Epithalon on radiosensitive organs
- Khavinson et al. 2023 — KE peptide regulates SIRT1, PARP1, PARP2 in MSC aging
- Khavinson et al. 2022 — Peptides regulating proliferative/inflammatory pathways in THP-1
- Khavinson et al. 2021 — Peptide regulation of gene expression (systematic review)
- Khavinson et al. 2020 — Peptides: Prospects for Use in Treatment of COVID-19
- Khavinson 2002 — Peptides and Ageing (review)
- PubChem — Lysylglutamic acid (CID 7010502)
- WADA 2026 Prohibited List
Frequently asked questions(6)
What is the difference between Vilon and Thymalin?
Thymalin is a polypeptide complex extracted from calf thymus gland containing a mixture of low-molecular-weight peptides. It is an approved pharmaceutical in Russia and has been used clinically since the early 1980s for immunocorrection. Vilon (Lys-Glu / KE) is one of the two primary active dipeptide fragments identified within Thymalin (the other being Thymogen / EW). While Thymalin has a broader mechanism due to its multi-peptide composition, Vilon represents the most targeted immunomodulatory component specifically associated with T-cell differentiation, thymocyte proliferation, and chromatin reactivation. Think of Vilon as a single active ingredient isolated from the complex mixture that is Thymalin.
Is Vilon safe? Are there side effects?
Human safety remains poorly characterized. The lifetime mouse study by Anisimov et al. (2000) noted that chronic Vilon administration caused no unfavorable effects on animal development, but Vilon increased mammary tumor development in one genetically susceptible mouse model. The frequently cited 6–8-year study evaluated Thymalin and Epithalamin, not isolated Vilon, and cannot establish Vilon's long-term safety. Vilon has few reported contraindications and has been noted as usable in patients with multiple chronic diseases (cardiovascular, renal, metabolic), but safety data comes from small studies with limited independent validation. Reported side effects are rare and minor: injection site irritation and transient fatigue. Caution is advised in individuals on active chemotherapy, those with autoimmune conditions without supervision, and during pregnancy/breastfeeding.
How does Vilon work at the molecular level?
Vilon's KE dipeptide selectively binds to specific DNA sequences — TCGA in double-stranded DNA, GCGG in classical B-form DNA, and GGGC in curved nucleosomal DNA. These sequences are found in the promoters of SIRT1, PARP1, and PARP2 genes. Through these interactions, Vilon upregulates SIRT1 (a key longevity sirtuin) by 6-8x in young cells, and downregulates PARP1/PARP2 (DNA damage response enzymes associated with inflammatory signaling when overactivated) during cellular aging. Vilon also induces deheterochromatinization — unrolling of condensed chromatin in elderly lymphocytes to release silenced genes — and modulates ERK1/2 signaling, TNF/IL-6 cytokine expression, and apoptotic pathways. This is direct epigenetic gene regulation rather than conventional receptor-mediated pharmacology.
Can Vilon be taken orally or must it be injected?
Both routes have been studied. Multiple studies administered Vilon orally (per os) to rats and demonstrated significant biological effects, including improved digestive enzyme activity and enhanced small intestine nutrient absorption (PMIDs 11586413, 12660839, 12420071). The dipeptide's extremely small size (275 Da, just two amino acids) may allow it to be absorbed relatively intact via intestinal peptide transporters (PepT1). However, subcutaneous injection bypasses digestive degradation and is the predominant route used in preclinical studies demonstrating lifespan extension and tumor inhibition. Both routes appear to be biologically active based on published evidence.
What sets Vilon apart from other peptide bioregulators?
Vilon is unique in several respects: (1) it is the shortest bioactive peptide documented with significant biological effects — just two amino acids; (2) it is one of the few peptides shown to induce selective chromatin remodeling (deheterochromatinization) in aging human lymphocytes; (3) it demonstrated 20-40% lifespan extension in mice with concurrent tumor suppression — an unusual combination of geroprotective and oncostatic properties; (4) it upregulates SIRT1 by 6-8x, directly linking it to one of the most well-validated longevity pathways; and (5) it has one of the longest research histories among Khavinson bioregulators, with studies spanning over 25 years.
Is the research on Vilon credible?
The research is published in legitimate peer-reviewed journals indexed in PubMed (Biogerontology, International Journal of Molecular Sciences, Bulletin of Experimental Biology and Medicine, Advances in Gerontology, Rejuvenation Research). The 2022 THP-1 study in IJMS represents collaboration with Italian researchers at the University of Chieti, providing some degree of international validation. However, the vast majority of studies originate from Khavinson's group or closely affiliated Russian institutions. Human clinical data is very limited, sample sizes are small, and no randomized double-blind placebo-controlled trials have been conducted. Independent replication by Western research groups is largely absent. The findings are internally consistent across many models, but the single-group origin remains a significant limitation.